Rewards Hub Apimeds Pharmaceuticals US, Inc. and MindWave Innovations Inc. have announced a merger, combining their expertise in biotech and Bitcoin capital solutions. The merger aims to create a dual-growth enterprise, with Apimeds focusing on non-opioid pain therapies and MindWave contributing its AI-driven Bitcoin yield platform and $NILA token-based ecosystem. E.F. Hutton acted as the exclusive M&A advisor and placement agent for the transaction, which included a $100 million private placement (PIPE).
Apimeds and MindWave Merge with $100M Private Equity Financing
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.